ARTICLE
7 August 2019

Pharmacovigilance Programme Of India & CDSCO Work Together For Patient Safety

SO
S&A Law Offices

Contributor

S&A Law Offices is a full-service law firm comprising experienced, well-recognized and accomplished professionals. S&A Law Offices aims to provide its clients (both domestic and international) with top-quality counsel and legal insights, which combines the Firm's innovative approach with comprehensive expertise across industries and a broad spectrum of modalities. Being a full-service law firm, we take pride in having the capability of providing impeccable legal solutions across various practice areas and industries and makes an endeavor to provide a 360 degree legal solution. With registered office at Gurugram and other strategically located offices in New Delhi, Mumbai, and Bengaluru, along with associate offices across India, S&A is fully equipped to provide legal services on a pan-India basis.
The Pharmacovigilance Programme of India, was first introduced in the year 2010 to improve safety of Indian population by monitoring drug related Adverse Drug Reactions collected via ADR monitoring centers ...
India Food, Drugs, Healthcare, Life Sciences

The Pharmacovigilance Programme of India, (PvPI) was first introduced in the year 2010 to improve safety of Indian population by monitoring drug related Adverse Drug Reactions (ADRs) collected via ADR monitoring centers across the country and the data was further sent to National Coordinating Centre (NCC)-PvPI.

NCC-PvPI receives suspected ADRs from all stakeholders, including Marketing Authorization Holders (MAHs), and reviews the safety information on a regular basis. It supports the Central Drugs Standard Control Organization (CDSCO) for further regulatory actions in the following manner:

  1. Signal Review Panel (SRP) of NCC-PvPI analyses the suspected ADRs and identifies India specific drug safety signals and recommends its findings to CDSCO for appropriate regulatory action.
  2. Subject Expert Committee (SEC) of CDSCO reviews the SRP recommendations, and if agreed with SRP, the SEC recommends the same to CDSCO for implementation or for inclusion of the ADRs in prescribing information (package inserts and drug safety labels). In case the SEC is not satisfied with SRP recommendations, it asks the NCC-PvPI to submit more Individual Case Safety Reports/signals to support their recommendation.
  3. CDSCO after considering recommendation of SEC, requests all State/UT Drugs Controllers to instruct all the manufacturers licensed for the said product/drugs to implement the same in prescribing information.

At present, a total of 47 drug safety signals, as identified and forwarded to CDSCO by SRP1, are categorized on the basis of their current regulatory status:

  1. Action taken by CDSCO
  2. Information sent to CDSCO by SRP, and is in process
  3. SEC recommended to CDSCO

1. Action taken by CDSCO: CDSCO requested all State/UT Drugs Controllers to instruct all manufacture of said product in their jurisdiction to implement the specified recommendations:

2. Information sent to CDSCO by SRP, and is in process:

3. Subject Expert Committee recommended CDSCO to direct the concerned manufacturers to incorporate following changes in package inserts/drug safety labels:


Note - The NCC-PvPI also publishes the preliminary analysis of ADRs at regular intervals in the form of Drug Safety Alert to inform the health care professionals, patients and consumers to closely monitor the possibility of ADR associated with the suspected drug, and if such reaction is encountered then report it to the NCC-PvPI.

Footnote

1. https://ipc.gov.in/images/pdf/PvPI_Recommendations_to_CDSCO.pdf

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More